Product
Help
Pricing
About
Jobs
Log in
Get started
Author
Add to collection
Sarah Worthington
Observed names:
S. Worthington,
Worthington, Sarah
Institutions:
University of Manchester,
Manchester University NHS Foundation Trust,
Royal Manchester Children's Hospital
Observed institutions:
University College Hospital,
University College London Hospitals NHS Foundation Trust,
The Royal Free Hospital,
University of Manchester,
Manchester University NHS Foundation Trust,
Royal Manchester Children's Hospital,
University College London
show all 7
OpenAlex ID:
A5077432013
Carfilzomib is an effective upfront treatment in AL amyloidosis patients with peripheral and autonomic neuropathy
2019
·
Richa Manwani
, Shameem Mahmood
, et al.
·
British Journal of Haematology
·
42
PDF
High response rates with single-agent belantamab mafodotin in relapsed systemic AL amyloidosis
2022
·
Jahanzaib Khwaja
, Joshua Bomsztyk
, et al.
·
Blood Cancer Journal
·
24
PDF
Cytomegalovirus reactivation after bortezomib treatment for multiple myeloma and light chain amyloidosis
2019
·
Faye A Sharpley
, Dunnya De‐Silva
, et al.
·
European Journal Of Haematology
·
21
PDF
Rapid response to single agent daratumumab is associated with improved progression-free survival in relapsed/refractory AL amyloidosis
2020
·
Oliver C. Cohen
, Maximillian H. Brodermann
, et al.
·
Amyloid
·
16
PDF
High patient satisfaction and increased physical activity following a remote multidisciplinary team multiple myeloma clinic
2023
·
Catherine S. Y. Lecat
, Abigail Fisher
, et al.
·
Supportive Care in Cancer
·
8
PDF
High Responses Rates with Single Agent Belantamab Mafodotin in Relapsed Systemic AL Amyloidosis
2023
·
Jahanzaib Khwaja
, Joshua Bomsztyk
, et al.
·
Blood
·
4
PDF
Utility of continuous glucose monitoring during pancreatic surgery in patients with congenital hyperinsulinism
2026
·
Sarah Worthington
, Chris Worth
, et al.
·
Frontiers in Endocrinology
·
1
PDF
Is Treatment with Bortezomib for Multiple Myeloma or Amyloidosis Associated with Cytomegalovirus Reactivation?
2015
·
Isobel Ramsay
, Dunnya De-silva
, et al.
·
Blood
·
1
Unusual [18F]FDOPA PET-CT maging of insulinomas in children
2026
·
Sameera Hannah Auckburally
, Ross J. Craigie
, et al.
·
EJNMMI Reports
PDF
Parent experiences of infant feeding in congenital hyperinsulinism: a thematic analysis
2026
·
Sarah Worthington
, Eleanor Ginbey
, et al.
·
Frontiers in Endocrinology
PDF
Inpatient continuous glucose monitoring halves the risk of hypoglycemia in patients with hyperinsulinism
2026
·
Chloe Chandra
, Shamani De Silva
, et al.
·
Frontiers in Endocrinology
PDF
NSP-25 Patient Reported Outcomes and Toxicities with Quadruplet Regimen Isa-VRd in Transplant Ineligible Newly Diagnosed Multiple Myeloma: A Single Centre Study
2026
·
Alex Greenwood
, Aviva Cerner
, et al.
·
Clinical Lymphoma Myeloma & Leukemia
NSP-22 Nurse Led Care in AL Amyloidosis: Impact of a Nurse Led Clinic on Enhancing Patient Experience, Improving Outcomes and Service Evaluation
2026
·
Sarah Worthington
, Alex Greenwood
, et al.
·
Clinical Lymphoma Myeloma & Leukemia
Patient Perspectives of Receiving Out-patient Step-up Dosing with Bispecific Antibodies (BsAb) for Relapsed Multiple Myeloma (MM)
2025
·
Jennifer Russell
, Catherine Lecat
, et al.
·
Clinical Lymphoma Myeloma & Leukemia
NSP-04 Patient Perceptions When Receiving Talquetamab for Triple Class Exposed Relapsed/ Refractory Myeloma: A Thematic Analysis
2024
·
Alexandra Greenwood
, Selina J Chavda
, et al.
·
Clinical Lymphoma Myeloma & Leukemia
P-144 Oral Symptom Assessment Using Patient Reported Outcomes (PRO) for Relapsed Multiple Myeloma Patients Treated with Talquetamab
2024
·
Rakesh Popat
, Alexandra Greenwood
, et al.
·
Clinical Lymphoma Myeloma & Leukemia
P-456 Survey on real world quality of life (QoL) issues relevant to distinct AL amyloidosis patient subgroups
2023
·
Sotirios Bristogiannis
, Jahanzaib Khwaja
, et al.
·
Clinical Lymphoma Myeloma & Leukemia
P-454 Patients views on the relevance of quality of life (QoL) questionnaires commonly applied to evaluate the QoL of patients with AL amyloidosis
2023
·
Sotirios Bristogiannis
, Jahanzaib Khwaja
, et al.
·
Clinical Lymphoma Myeloma & Leukemia
P918: High Responses Rates With Single Agent Belantamab Mafodotin in Relapsed Systemic Al Amyloidosis
2022
·
J. Khwaja
, J. Bomsztyk
, et al.
·
HemaSphere
Melphalan 140mg/m“2” significantly reduces 5 year progression free survival in multiple myeloma patients receiving a peripheral blood autologous stem cell transplant compared with melphalan 200mg/m“2”
2015
·
C. Attwood
, E. Nicholson
, et al.
·
Clinical Lymphoma Myeloma & Leukemia
Show more works
View as search
Works count:
21
Citation count:
118
H-index:
5
I10-index:
4
Year
Topic
Type